1. Home
  2. EVO vs PCRX Comparison

EVO vs PCRX Comparison

Compare EVO & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.73

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$22.46

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVO
PCRX
Founded
1993
2006
Country
Germany
United States
Employees
4553
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
934.1M
1.0B
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
EVO
PCRX
Price
$2.73
$22.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$7.00
$30.25
AVG Volume (30 Days)
95.9K
533.8K
Earning Date
04-08-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.44
EPS
N/A
0.07
Revenue
N/A
$541,533,000.00
Revenue This Year
$1.37
$6.78
Revenue Next Year
$10.05
$8.54
P/E Ratio
N/A
$324.86
Revenue Growth
N/A
26.04
52 Week Low
$2.31
$18.80
52 Week High
$4.80
$27.64

Technical Indicators

Market Signals
Indicator
EVO
PCRX
Relative Strength Index (RSI) 41.07 40.41
Support Level $2.32 $21.80
Resistance Level $3.78 $24.20
Average True Range (ATR) 0.09 1.23
MACD -0.06 -0.25
Stochastic Oscillator 19.16 5.58

Price Performance

Historical Comparison
EVO
PCRX

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: